Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.40 |
| ▸ | TK2 | O00142 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053437 | 0.90 | TK1 (0.42) | TK1TK2LMNAALBBLM | |
| SCHEMBL27043055 | 0.84 | TK2 (0.39) | TK1TK2LMNAALBBLM | |
| SCHEMBL3797592 | 0.84 | TK1 (0.40) | TK1TK2LMNAALBBLM | |
| SCHEMBL29260148 | 0.82 | TK1 (0.39) | TK1TK2LMNAALBBLM | |
| SCHEMBL2877649 | 0.81 | TK1 (0.43) | TK1TK2LMNAALBBLM | |
| SCHEMBL6753364 | 0.81 | TK1 (0.41) | TK1TK2LMNAALBBLM | |
| SCHEMBL28182722 | 0.80 | TK2 (0.46) | TK1TK2LMNAALBBLM | |
| SCHEMBL13387567 | 0.80 | TK1 (0.44) | TK1TK2LMNAALBBLM | |
| SCHEMBL27878939 | 0.80 | TYMP (0.46) | TK1TK2LMNAALBBLM | |
| SCHEMBL28190357 | 0.79 | TK2 (0.47) | TK1TK2LMNAALBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3925965-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-22 | — | — | EP | disclosed |
| CN-113474353-A | 5' -modified nucleoside and nucleotide using the same | 国立大学法人大阪大学 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020166551-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | TK1 99/4885TK2 173/4885LMNA 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.